


EVG-COBI-TDF-FTC versus ATV + RTV + TDF-FTC in Women  
**Study 128 (WAVES)**

# EVG-COBI-TDF-FTC versus ATV + RTV + TDF-FTC (in Women)

## WAVES Study: Design


- **Background:** Randomized, double-blind, phase 3 trial comparing elvitegravir-cobicistat-tenofovir-emtricitabine with atazanavir + ritonavir + tenofovir DF-emtricitabine in women
- **Inclusion Criteria** (n = 575)
  - Antiretroviral-naïve women
  - Age ≥18 years
  - HIV RNA ≥500 copies/mL
  - Any CD4 count
- **Treatment Arms**
  - Elvitegravir-Cobicistat-TDF-FTC
  - Atazanavir + Ritonavir + TDF-FTC



# EVG-COBI-TDF-FTC versus ATV + RTV + TDF-FTC (in Women)


## WAVES Study: Result

Week 48 Virologic Response



# EVG-COBI-TDF-FTC versus ATV + RTV + TDF-FTC (in Women) WAVES Study: Result

Week 48 Virologic Response



# EVG-COBI-TDF-FTC versus ATV + RTV + TDF-FTC (in Women)

## WAVES Study: Common Adverse Events

Treatment Emergent Adverse Events in $\geq 10\%$ of Subjects in Either Group		
	<b>EVG-COBI-TDF-FTC</b> (n = 289)	<b>ATV + RTV + TDF-FTC</b> (n = 286)
Headache	16%	15%
Upper Respiratory Tract Infection	16%	15%
Malaria	11%	8%
Nausea	15%	14%
Vomiting	10%	6%
Jaundice	<1%	11%
Icterus	<1%	12%

Source: Squires L, et al. Lancet HIV. 2016;3:e410-20.

# EVG-COBI-TDF-FTC versus ATV + RTV + TDF-FTC (in Women) WAVES Study: Conclusions

**Interpretation:** “WAVES shows that clinical trials of ART regimens in global and diverse populations of treatment-naive women are possible. The findings support guidelines recommending integrase inhibitor based regimens in first-line antiretroviral therapy.”

# Acknowledgments

The **National HIV Curriculum** is supported by the Health Resources and Services Administration (HRSA) of the U.S. Department of Health and Human Services (HHS) as part of a financial assistance award totaling \$1,021,448 with 0% financed with non-governmental sources. The contents are those of the author(s) and do not necessarily represent the official views of, nor an endorsement, by HRSA, HHS, or the U.S. Government. For more information, please visit [HRSA.gov](http://HRSA.gov). This project is led by the University of Washington's Infectious Diseases Education and Assessment (IDEA) Program.

